https://www.selleckchem.com/sc....reening/fda-approved
2; 95% CI, 3.1-33.3; P .001; and PPIs 15 days vs ≥30 days; HR, 20.4; 95% CI, 2.2-192.3; P .001). The use of PPIs increased the risk of EBI after PTBS in patients with unresectable MBO. Furthermore, the risk of EBI increased with a prolonged duration of PPIs use. The use of PPIs increased the risk of EBI after PTBS in patients with unresectable MBO. Furthermore, the risk of EBI increased with a prolonged duration of PPIs use. To evaluate the adherence to treatment with tofacitinib in patients with rheumatoi
Like
Comment
Share
